Slides
Page 1
Fiscal First Quarter 2026 November 2025
Page 2
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 This Presentation is for informational purposes only and does not constitute an offer or invitation to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, assets, business, debt or other financial instruments of the Company or any of its affiliates, and shall not form the basis of any contract, nor shall it be construed in any manner as a commitment on the part of any person to proceed with any transaction. Any reproduction of this Presentation, in whole or in part, or the disclosure of its contents, without the prior consent of the Company is prohibited. By accepting this Presentation, each recipient agrees to use this Presentation for the sole purpose of evaluating. Forward-Looking Statements This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful and (ii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled “Risk Factors” in the company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward- looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law. Disclaimer Industry and Market Data Unless otherwise noted, the forecasted industry and market data contained in the assumptions for the projections are based upon the Company’s management estimates and industry and market publications and surveys. The information from industry and market publications has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. The Company has not independently verified any of the data from third-party sources, nor has the Company ascertained the underlying economic assumptions relied upon therein. While such information is believed to be reliable for the purposes used herein, none of the Company, its affiliates, their respective directors, officers, employees, members, partners, shareholders or agents makes any representation or warranty with respect to the accuracy of such information. These materials are highly sensitive and confidential and being supplied to you solely for your information and for use in this Presentation. Financial Information Presentation Historical financial information of Bioceres has been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). Investors should note that IFRS differs from generally accepted accounting principles in the United States (“US GAAP”), and investors should consult their own professional advisors for an understanding of the difference between IFRS and US GAAP and how those differences might affect such financial statements. Use of Non-IFRS Financial Measures This Presentation includes certain non-IFRS financial measures. These non-IFRS measures are an addition, and not a substitute for or superior to measures of financial performance prepared in accordance with IFRS and neither should be considered as an alternative to net income or any other performance measures derived in accordance with IFRS or as an alternative to cash flows from operating activities as a measure of our liquidity. The Company believes that these non-IFRS measures of financial results provide useful supplemental information to investors about the Company and its results. The Company’s management uses these non-IFRS measures to evaluate the Company’s financial and operating performance and make day-to-day financial and operating decisions. The Company also believes that these non-IFRS measures are helpful to investors because they provide additional information about trends in the Company’s core operating performance prior to considering the impact of capital structure, depreciation, amortization and taxation on its results. However, there are a number of limitations related to the use of these non-IFRS measures and their nearest IFRS equivalents. For example, other companies may calculate non-IFRS measures differently, or may use other measures to calculate their financial performance, and therefore the Company’s non-IFRS measures may not be directly comparable to similarly titled measures of other companies. In this presentation, we discuss non-IFRS measures as forward-looking non-IFRS measures. Copyrights and Trademarks All materials contained in this Presentation are protected by copyright laws and may not be reproduced, republished, distributed, transmitted, displayed, broadcast or otherwise exploited in any manner. This Presentation contains trademarks, service marks, and trade names belonging to the Company, its affiliates and other entities and cannot be used without express written consent. Trademarks, service marks, copyrights and trade names referred to in this Presentation, including logos, may appear without the ®, © or TM symbols, but the lack of such symbols is not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other entities’ trademarks, service marks, copyrighted material or trade names to imply a relationship or affiliation with, or endorsement or sponsorship of, the Company by any other entities or persons 02
Page 3
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 03 Key Business & Financial Highlights 1. Please refer to “Use of non-IFRS financial information” for information our use of Adjusted EBITDA and its reconciliation from the most comparable financial measure. ● Total revenues were $77.5 million in 1Q26, a 17% decline year over year, reflecting the expected reduction from the seed model transition and the pruning of low-margin and working-capital- intensive sales. ● Gross margin was 47%, driven by a more profitable product mix. Gross profit was $36.2 million, a 3% reduction from last year. ● Operating profit and Adjusted EBITDA increased 200% and 61% year over year, respectively, reflecting margin expansion and cost discipline. Operating profit was $7.1 million for the quarter, net loss was $7.5 million and Adjusted EBITDA1 was $13.6 million. ● 1Q26 reflected clear progress on the priorities set for the year: margin expansion, year-over- year reduction in working capital, and reduced operating expenses.
Page 4
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 Reduced Operating Expenses 1. Excluding D&A, stock-based compensation and transaction expenses. 46.7%40.2% 1Q25 Margin Expansion Working Capital Management • Gross margin expanded significantly • More profitable product mix (shift away from lower margin products) • Margin expansion in key categories (adjuvants, bioprotection, biostimulants, seed packs) $5.9 M reduction in Opex YoY1 Variable expenses over sales (from 8% to 5%) Fixed SG&A expenses (personnel, mobility) -15% YoY • Working capital continued to improve YoY and sequentially • Maintain ~4 months of sales target 1Q26 $23.6M$29.5M 1Q25 1Q26 YoY change % -20% $55 M YoY reduction in Working Capital Business Priorities 04
Page 5
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 ($ Million) Revenue Bridge 05 Key Drivers Revenue performance in line with previously communicated strategy: expected reduction from the seed model transition and the pruning of low-margin and working-capital- intensive sales. Revenue impacted by timing of sales in certain Latam markets, particularly Uruguay. Argentina recovery remains gradual. 1Q26 Revenue by Segment 93.2 1Q25 77.5 1Q26 (7.9) Crop Protecion Crop Nutrition (7.2) (0.6) Seeds ($ Million) 1Q26 77.5 - 17% YoY Total Revenue Seed & Integrated Products Crop Nutrition Crop Protection 12.6 39.925.1 -37% -16%-2%
Page 6
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 ($ Million) 1Q26 1Q26 Gross Profit Bridge 37.5 1Q25 36.2 1Q26 36.2 - 3% YoY (1.0) Crop Protecion 06 Gross Profit Seed & Integrated Products Crop Nutrition Crop Protection Crop Nutrition (0.8) 46.7%40.2% 0.5 Seeds Gross margin 7.5 17.611.1 Despite lower revenues, gross profit declined only slightly, reflecting a more profitable product mix and reduced contribution from low-margin downstream seed sales and third- party products. Gross margin expanded meaningfully from 40% to 47%. +7% -5%-6% Key Drivers 1Q26 Gross Profit by Segment
Page 7
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 13.6 1Q26 ($ Million) 8.5 Adj. EBITDA1 1Q25 Gross Profit2 Other income or expenses Adj. EBITDA1 1Q26 1. Please refer to “Use of non-IFRS financial information” for information regarding our use of Adjusted EBITDA and its reconciliation from the most comparable financial measure. 2. Gross profit and operating expenses excluding D&A, stock-based compensation and transaction expenses. (0.6) 07 (1.1) 5.9 1Q26 Adjusted EBITDA1 Opex Adj. EBITDA increased 61% YoY. A more profitable product mix, together with tighter operating discipline, translated into stronger operating performance. JV results 0.9
Page 8
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 Net Debt Balance Sheet & Cash Position 3Q 4Q ($ Million) ($ Million) 16.6 6.8x Adj. EBITDA1 Net Debt 1Q26 Cash & Equivalents2Current Debt 225.9 1. Please refer to “Use of non-IFRS financial information” for information regarding our use of Adjusted EBITDA and its reconciliation from the most comparable financial measure. 2. Cash & Equivalents include other cash management short-term investments. 08 3Q 4Q ($ Million) 8.0x Adj. EBITDA1 Net Debt 4Q25 225.5 Acceleration notice received from noteholders Company disputes allegations and purported acceleration Payments remain current Capital Structure Update Non-current Debt 34.7 188.7222.0 Accelerated Debt 103.6* Accelerated Debt 102.3* 38.2 53.8 *Includes $4.8M cost of acceleration *Includes $7.4M cost of acceleration
Page 9
Exhibits BIOCERES CROP SOLUTIONS
Page 10
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 Unaudited Consolidated Statement of Comprehensive Income Three-month period ended 9/30/2025 Three-month period ended 9/30/2024 Revenues from contracts with customers 77.3 92.6 Initial recognition and changes in the fair value of biological assets at the point of harvest 0.2 0.7 Cost of sales (41.3) (55.8) Gross profit 36.2 37.5 % Gross profit 47% 40% Operating expenses (28.9) (34.6) Share of profit of JV 0.3 (0.6) Changes in the net realizable value of agricultural products after harvest (0.3) 0.6 Other income or expenses, net (0.2) (0.5) Operating profit 7.1 2.4 Finance result (12.6) (9.8) Profit before income tax (5.5) (7.5) Income tax (2.1) 1.3 Profit / (Loss) for the period (7.5) (6.2) Other comprehensive Profit / (Loss) (0.3) (0.0) Total comprehensive Profit / (Loss) (7.8) (6.2) Profit / (loss) for the period attributable to: Equity holders of the parent Non-controlling interests (7.4) (6.4) (0.1) 0.2 (7.5) (6.2) Total comprehensive Profit / (Loss) attributable to: Equity holders of the parent (7.7) (6.4) Non-controlling interests (0.1) 0.2 (7.8) (6.2) 10
Page 11
BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 11 Unaudited Consolidated Statement of Financial Position ASSETS 9/30/2025 06/30/2025 CURRENT ASSETS Cash and cash equivalents 15.5 32.7 Other financial assets 1.1 2.0 Trade receivables 158.4 165.9 Other receivables 16.6 15.9 Recoverable income tax 1.7 1.9 Inventories 88.6 87.6 Biological assets 1.2 2.4 Total current assets 283.2 308.3 NON-CURRENT ASSETS Trade receivables 5.1 2.5 Other receivables 20.4 23.7 Recoverable income tax 0.0 0.0 Deferred tax assets 5.4 4.9 Investments in joint ventures and associates 39.4 39.4 Investment properties 0.6 0.6 Property, plant and equipment 74.0 74.6 Intangible assets 178.6 181.2 Goodwill 112.2 112.2 Right of use asset 15.8 16.4 Total non-current assets 451.7 455.3 Total assets 734.8 763.6 LIABILITIES 9/30/2025 06/30/2025 CURRENT LIABILITIES Trade and other payables 107.1 96.4 Borrowings 85.1 119.7 Employee benefits and social security 5.5 6.2 Deferred revenue and advances from customers 2.3 4.3 Income tax payable 3.0 0.5 Consideration for acquisition 0.8 1.8 Secured notes 103.6 102.3 Lease liabilities 3.8 6.9 Total current liabilities 311.3 338.0 NON-CURRENT LIABILITIES Trade and other payables 36.9 48.5 Borrowings 53.8 38.2 Deferred revenue and advances from customers 1.8 1.4 Joint ventures and associates 0.8 1.0 Deferred tax liabilities 28.3 30.1 Provisions 1.2 1.3 Consideration for acquisition 0.4 0.4 Lease liabilities 12.2 9.5 Total non-current liabilities 135.3 130.4 Total liabilities 446.5 468.4 EQUITY Equity attributable to owners of the parent 258.6 265.4 Non-controlling interests 29.7 29.8 Total equity 288.3 295.2 Total equity and liabilities 734.8 763.6
Page 12
Non-IFRS Financial Measures Adjusted EBITDA The company defines adjusted EBITDA as net income/(loss) exclusive of financial income/(costs), income tax benefit/(expense), depreciation, amortization, share-based compensation, and one-time transactional expenses. Management believes that adjusted EBITDA provides useful supplemental information to investors about the company and its results. Adjusted EBITDA is among the measures used by the management team to evaluate the company’s financial and operating performance and make day-to-day financial and operating decisions. In addition, adjusted EBITDA and similarly titled measures are frequently used by competitors, rating agencies, securities analysts, investors and other parties to evaluate companies in the same industry. Management also believes that adjusted EBITDA is helpful to investors because it provides additional information about trends in the company’s core operating performance prior to considering the impact of capital structure, depreciation, amortization and taxation on results. Adjusted EBITDA should not be considered in isolation or as a substitute for other measures of financial performance reported in accordance with IFRS. Adjusted EBITDA has limitations as an analytical tool, including: • Adjusted EBITDA does not reflect changes in, including cash requirements for working capital needs or contractual commitments. • Adjusted EBITDA does not reflect financial expenses, or the cash requirements to service interest or principal payments on indebtedness, or interest income or other financial income. • Adjusted EBITDA does not reflect income tax expense or the cash requirements to pay income taxes. • Although depreciation and amortization are non-cash charges, the assets being depreciated or amortized often will need to be replaced in the future, and adjusted EBITDA does not reflect any cash requirements for these replacements. • Although share-based compensation is a non-cash charge, adjusted EBITDA does not consider the potentially dilutive impact of share-based compensation. • Other companies may calculate adjusted EBITDA and similarly titled measures differently, limiting its usefulness as a comparative measure. The company compensates for the inherent limitations associated with using adjusted EBITDA through disclosure of these limitations, presentation in the combined financial statements in accordance with IFRS and reconciliation of adjusted EBITDA to the most directly comparable IFRS measure, income/(loss) for the period or year. Adjusted EBITDA reconciliation from Profit/(Loss) for the period 16 BIOCERES CROP SOLUTIONS FIRST QUARTER 2026 ($ Million) 1Q25 1Q26 Profit/(loss) for the period (6.2) (7.5) Income tax (1.3) 2.1 Financial results 9.8 12.6 D&A 5.3 5.8 Stock-based compensation charges 0.8 0.0 Transaction expenses - 0.6 Adjusted EBITDA 8.5 13.6 12
Page 13
Contact Us: Investor Relations Investorrelations@biocerescrops.com // Investors.biocerescrops.com